There are provided, inter alia, methods for decreasing mucus elasticity or decreasing mucus viscosity in a subject in need thereof, the methods including administering to the subject an effective amount of a dithiolsaccharide mucolytic agent, and compounds and pharmaceutical compositions useful for the methods.

There are provided, inter alia, methods for decreasing mucus elasticity or decreasing mucus viscosity in a subject in need thereof, the methods including administering to the subject an effective amount of a dithiolsaccharide mucolytic agent, and compounds and pharmaceutical compositions useful for the methods.

Provided is a compound of the general formula (I):

##STR00001##

The compound of formula (I) is suitable for treating pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a mammal. Also provided is a method for treatment of pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a human subject having a galectin-3 level indicative of pulmonary fibrosis or exacerbation of symptoms as well as a method for making said compound.

Provided is a compound of the general formula (I):

##STR00001##

The compound of formula (I) is suitable for treating pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a mammal. Also provided is a method for treatment of pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a human subject having a galectin-3 level indicative of pulmonary fibrosis or exacerbation of symptoms as well as a method for making said compound.

Provided is a compound of the general formula (I): ##STR00001## The compound of formula (I) is suitable for treating pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a mammal. Also provided is a method for treatment of pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a human subject having a galectin-3 level indicative of pulmonary fibrosis or exacerbation of symptoms as well as a method for making said compound.

Provided is a compound of the general formula (I): ##STR00001## The compound of formula (I) is suitable for treating pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a mammal. Also provided is a method for treatment of pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a human subject having a galectin-3 level indicative of pulmonary fibrosis or exacerbation of symptoms as well as a method for making said compound.

A hybrid inorganic-organic composite comprising a nanostructure of a metal chalcogenide and at least one compound comprising an organic cyclic moiety, wherein the compound is linked to the nanostructure, is provided. A nanotube of metal chalcogenide (e.g., metal dichalcogenide) nanostructure having attached to at least one surface thereof one or more selected chemically reactive nanoparticles is also provided.

A hybrid inorganic-organic composite comprising a nanostructure of a metal chalcogenide and at least one compound comprising an organic cyclic moiety, wherein the compound is linked to the nanostructure, is provided. A nanotube of metal chalcogenide (e.g., metal dichalcogenide) nanostructure having attached to at least one surface thereof one or more selected chemically reactive nanoparticles is also provided.

A sulfinate glycosyl donor of formula I and a method for preparing same as well as use thereof in preparing a glycoside compound including a thioglycoside compound and a carbon glycoside compound are provided. The sulfinate glycosyl donor has a special sulfinate structure. When the sulfinate glycosyl donor is used as a raw material to prepare the glycoside compound, an additional initiator does not need to be added, such that the production cost is saved, the generation of byproducts is reduced, and the glycoside compound with a purity greater than 98% is obtained. The sulfinate glycosyl donor can be used in the preparation of the glycoside compound such as the thioglycoside compound and the carbon glycoside compound.

A sulfinate glycosyl donor of formula I and a method for preparing same as well as use thereof in preparing a glycoside compound including a thioglycoside compound and a carbon glycoside compound are provided. The sulfinate glycosyl donor has a special sulfinate structure. When the sulfinate glycosyl donor is used as a raw material to prepare the glycoside compound, an additional initiator does not need to be added, such that the production cost is saved, the generation of byproducts is reduced, and the glycoside compound with a purity greater than 98% is obtained. The sulfinate glycosyl donor can be used in the preparation of the glycoside compound such as the thioglycoside compound and the carbon glycoside compound.